Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

Healthtrust
Fish and Richardson
Julphar
Harvard Business School
Chubb
Johnson and Johnson

Generated: September 22, 2019

DrugPatentWatch Database Preview

Patent: 9,572,788

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,572,788
Title:Cell permeable inhibitors of anaphase promoting complex
Abstract: The disclosure provides compositions and methods for treating cell cycle disorders. Compositions of the disclosure include proTAME, a prodrug analog of TAME and apcin, the combination of which inhibits an activity or function of the anaphase promoting complex (APC) by a synergistic mechanism.
Inventor(s): King; Randall (Newton, MA), Zeng; Xing (Brookline, MA), Sackton; Katharine L. (Somerville, MA)
Assignee: President and Fellows of Harvard College (Cambridge, MA)
Application Number:14/276,994
Patent Claims:see list of patent claims

Details for Patent 9,572,788

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Genentech RITUXAN rituximab VIAL 103705 001 1997-11-26   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX search
Genentech HERCEPTIN trastuzumab VIAL; INTRAVENOUS 103792 001 1998-09-25   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 001 2001-05-07   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX Orphan search
Genzyme CAMPATH alemtuzumab VIAL; INTRAVENOUS 103948 002 2001-05-07   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX Orphan search
Genzyme LEMTRADA alemtuzumab INJECTABLE;INJECTION 103948 003 2001-05-07   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX Orphan search
Spectrum Pharms ZEVALIN ibritumomab tiuxetan INJECTABLE; INJECTION 125019 001 2002-02-19   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX Orphan search
Imclone ERBITUX cetuximab VIAL; INTRAVENOUS 125084 001 2004-06-18   Try a Free Trial President and Fellows of Harvard College (Cambridge, MA) 2037-02-28 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Chubb
Fish and Richardson
McKinsey
Moodys
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.